Sanjiv J. Shah, MD is the Stone Endowed Professor; Director of Research for the Bluhm Cardiovascular Institute; Director, Center for Deep Phenotyping and Precision Medicine in the Insitute for Augmented Intelligence in Medicine; and Director of the Heart Failure with Preserved Ejection Fraction (HFpEF) Program at Northwestern University Feinberg School of Medicine. Dr. Shah’s clinical expertise and research program are focused HFpEF, which is one of the most prevalent cardiovascular diseases and for which there are few proven treatments. In 2007, Dr. Shah started the first dedicated HFpEF program in the world at Northwestern University. The Northwestern University HFpEF program has served as a model for several other similar programs in the United States and throughout the world. Dr. Shah has been continuously funded by grants from the American Heart Association and the National Institutes of Health since 2008. He directs a laboratory that investigates the pathogenesis of heart failure; conducts multicenter clinical trials of novel therapeutics for heart failure, pulmonary hypertension, and cardiac amyloidosis; and develops novel techniques for machine learning and artificial intelligence for the classification, diagnosis, and tracking of cardiovascular diseases. His is currently the principal investigator of the Data Translation Center for the NIH HeartShare Study, which is a large scale, prospective, multi-center initiative to apply next generation phenomics to identify heart failure subtypes and treatment targets. Dr. Shah’s research, which has spans basic research in animal models, clinical physiologic studies, human clinical trials, and population-based epidemiology studies, has highlighted the heterogeneity and systemic nature of the HFpEF syndrome, and has improved the understanding of the risk factors, pathogenesis, and pathophysiology of HFpEF. He has also pioneered the use of machine learning for novel classification of cardiovascular diseases. Dr. Shah has served as the international principal investigator, executive committee member, or steering committee member for > 35 multicenter randomized clinical trials and studies in heart failure. His work on clinical trials has contributed to the development of the first proven treatment for transthyretin cardiac amyloidosis, a highly fatal disease. Current research in his laboratory is focused on the molecular pathogenesis of abnormal cardiac mechanics; artificial intelligence for the automated interpretation of echocardiograms; adipocyte-endothelium-cardiomyocyte interactions; and the development of novel therapeutics for heart failure and microvascular dysfunction. Dr. Shah has published >400 peer-reviewed scientific research publications in leading medical journals, a textbook on cardiovascular genetics, and handbooks on internal medicine and cardiovascular disease. He is an associate editor of JAMA Cardiology, he is on the editorial board of Circulation: Heart Failure, and he has served as guest editor for the Journal of Cardiovascular Translational Research. His work has been cited over 18,000 times (Scopus, October 2021). Dr. Shah has mentored > 50 individuals throughout his career, including undergraduates, medical students, post-doctoral fellows, cardiology fellows, and early-stage faculty. He has received multiple teaching awards, including the George Joost MD, Teach of the Year Award at the Feinberg School of Medicine and the American College of Cardiology W. Proctor Harvey, MD Teaching Award. As an internationally recognized leading authority on HFpEF, Dr. Shah routinely lectures at international cardiology meetings, continuing medical education meetings, and academic institutions (including honorary lectures at Johns Hopkins University and Tufts University).

View full profile